What is the significance of HER2 amplification and how does it affect the use of antibody-drug conjugates (ADCs)?
Joseph GLIGOROV
oncologist, Paris, France
oncologist, Paris, France
New User? Click here to register
Text generated by AI based on an exclusive interview, revised and reviewed by
Jean-Philippe SPANO
Chairman of Oncology department , University hospital Pitié-Salpétrière, Paris, France
Yazid BELKACEMI
Oncologue-Radiothérapeute, Créteil, France
Copyright © 2026 - BCU